For ALK, 2008 was a good year with breakthrough research results and
satisfactory financial results. ALK met its financial forecast and generated a
five-fold increase of the underlying operating profit before contributions from
the company's US-based partner, Schering-Plough. Profit before tax was DKK 157
million. For 2009, ALK expects a continued double-digit growth in the company's
core business, sales of allergy vaccines, and a significant increase in the
company's operating profit.

The full report is attached to this announcement.

ALK invites investors and analysts to a meeting with Management tomorrow at
9.00 a.m. (CET) at the company headquarters 6-8, Bøge Allé, Hørsholm, Denmark.
The meeting will be held in English and webcast live on www.alk-abello.com. It
will be possible to call in with questions.
Danish participants must call in on telephone +45 70 26 50 40 before 8.55 a.m.
(CET), and international participants must call in on telephone +44 208 817
9301 before 8.55 a.m. (CET).

ALK-Abelló A/S


Jens Bager
President and CEO

For further information please contact:
Jens Bager, President and CEO, tel. +45 45 74 75 76

Investor Relations: Per Plotnikof, tel +45 45 74 75 27, mobile +45 22 61 25 25
Press: Jacob Frische, tel +45 45 74 75 51, mobile +45 22 24 75 51

fm-04-09-uk.pdf